1. Optimizing therapy for nodal marginal zone lymphoma
by Catherine Thieblemont, Thierry Molina, and Frédéric Davi
Blood
Volume 127(17):
April 28, 2016
©2016 by American Society of Hematology

2. Standard first-line treatment approaches in adult NMZL not associated with HCV. Treatment follows the approach used with follicular lymphoma. *R-bendamustine > R-CHOP: PFS, 69.5 vs 32.1 months (hazard ratio, 0.58; 95% CI, ; P < .0001).49 **Fludarab...
Standard first-line treatment approaches in adult NMZL not associated with HCV. Treatment follows the approach used with follicular lymphoma. *R-bendamustine > R-CHOP: PFS, 69.5 vs 32.1 months (hazard ratio, 0.58; 95% CI, ; P < .0001).49 **Fludarabine > chlorambucil; PFS, 36.3 vs 27.1 months, P = ; because of the toxicity profile, R-fludarabine or R-fludarabine-cyclophosphamide should only be proposed to patients <70 years of age. Note: There is no evidence for recommending maintenance with rituximab or an intensive treatment plus autologous stem cell transplantation in first line.
Catherine Thieblemont et al. Blood 2016;127:
©2016 by American Society of Hematology